GF Securities, GF Xinde Investment Management Co., Ltd. (“GF Xinde”) and Bay City Capital, LLC (“Bay City Capital”).
Bay City Capital and GF Xinde announced a new life sciences fund — Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempted limited partnership. This fund will invest in companies across all stages of development with a focus on novel and transformative biopharmaceutical investments in geographies including the United States, Canada, Western Europe and China. This unique collaboration aims to capitalize on the strengths of Bay City Capital in deal sourcing and execution in the Western markets and GF Xinde’s strategic network in China for value-add partnerships and financing opportunities for the fund. “China is the fastest growing life science market and is the world’s second largest pharmaceutical market,” said David Beier, Managing Director of Bay City Capital. “Our collaboration with GF Xinde can provide valuable insights for this important healthcare segment.”
GF Xinde is a private equity investment subsidiary wholly owned by GF Securities, leading A+H share listed securities company whose clients comprise 80 percent of the listed pharmaceutical companies in China and which has deep connections to the Chinese biotech and pharma industries. “The establishment of Bay City Capital GF Xinde International Life Sciences USD Fund is another important step in GF Xinde’s China life science strategy. “Access to innovation is a high priority for Chinese companies and this fund will provide a window into cutting-edge technologies and assets in the United States and beyond and serve as a cross-border healthcare investment and technology-licensing portal for both foreign and Chinese healthcare companies,” said Dr. Zeng Hao, Chairman of GF Xinde.